TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

▤ Summary

TuHURA Biosciences closed a $12.5 million private equity financing and received an additional $3.0 million from warrant exercises. The company plans to use the capital to fund its proposed merger with Kineta, start a Phase 3 trial for IFx-2.0, and advance Kinetas VISTA-inhibiting antibody into a Phase 2 study. The financing is milestone-based, with some proceeds tied to FDA and trial-initiation events and the merger closing. TuHURA also agreed to file a resale registration statement for the shares and warrant shares issued in the offering.

$ Funding

▦ Linked Companies